The PREPARATORY – 5 study was a one-arm, open-label pilot trial of daily TDF/FTC-based pre-exposure prophylaxis among 50 men who have sex with men (MSM) at high risk of sexually acquired HIV infection in Toronto, Canada. It was conducted from November 2014 to June 2016. Participants who screened eligible received PrEP and associated clinical care over a one-year period with quarterly follow-up. Its primary objectives were to quantify participants’ self-reported overall acceptability of PrEP and to estimate the level of community interest in PrEP. PREPATORY-5 was conducted as time when there were important questions about the acceptability and feasibility of providing PrEP more widely, and was the first real-world demonstration project of PrEP in Canada.
You can read findings from this study here: Trends in the awareness, acceptability, and usage of HIV pre-exposure prophylaxis among at-risk men who have sex with men in Toronto.
Read more on clinicaltrials.gov.
This study was made possible through grants from CIHR, the Ontario HIV Treatment Network, the Canadian HIV Trials Network and study drug provided by Gilead Sciences.